DSGN

Design Therapeutics Stock Price

27.535
0.445 (1.64%)
Upgrade to Real-Time
Regular Market
27.535

Low
18.55

52 Week Range

High
50.00

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Design Therapeutics Inc DSGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.445 1.64% 27.535 11:17:03
Open Price Low Price High Price Close Price Prev Close
27.44 27.07 27.82 27.09
Bid Price Ask Price Spread News
27.34 27.73 0.39 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
933 111,333 $ 27.45 $ 3,055,862 92,960 18.55 - 50.00
Last Trade Time Type Quantity Stock Price Currency
11:17:03 100 $ 27.535 USD

Design Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.53B 55.62M 27.45M $ 226.00k $ - -0.30 -46.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -11.98M 2.00%

more financials information »

Design Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DSGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week26.4428.4825.4327.3677,0881.104.14%
1 Month22.7128.4821.0026.5279,8214.8321.25%
3 Months28.0050.0018.5528.17155,931-0.465-1.66%
6 Months28.0050.0018.5528.17155,931-0.465-1.66%
1 Year28.0050.0018.5528.17155,931-0.465-1.66%
3 Years28.0050.0018.5528.17155,931-0.465-1.66%
5 Years28.0050.0018.5528.17155,931-0.465-1.66%

Design Therapeutics Description

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.


Your Recent History
NASDAQ
DSGN
Design The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.